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Abstract
Complete resection of early-stage non–small cell lung cancer (NSCLC) is potentially curative, yet approximately 50%
of patients are at risk for developing metastatic recurrence. Met, the receptor for hepatocyte growth factor (HGF) is a
receptor tyrosine kinase with demonstrated roles in regulating cellular proliferation, motility, morphogenesis, and
apoptosis. Met receptor and its ligand, HGF, are commonly overexpressed in NSCLC, and their overexpression
has been associated with poor prognosis, which could potentially involve a paracrine and/or autocrine activation
loop. However, there is as yet no direct evidence that HGF-Met signaling directly promotes metastasis in NSCLC
cells. Using retroviral transduction, we overexpressed the human c-met and hgf complementary DNA, alone or in
combination in the NCI-H460 human large cell carcinoma cell line. The HGF/Met co-overexpressing (H460-HGF/
Met) cells demonstrated enhanced tumorigenicity in xenograft SCID mice. When these cells are implanted ortho-
topically into the lungs of nude rats, only the H460-HGF/Met cells showed higher spontaneous metastases to distant
organs including bone, brain, and kidney. These results provide evidence that autocrine overactivation of the Met-
HGF loop enhances systemic metastases in NSCLC. Targeted interference of this loop may potentially be an effec-
tive adjuvant therapy to improve survival of early-stage NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer-related death in North
America and worldwide [1–3]. The 5-year survival rate of lung carci-
noma has remained relatively unchanged at 15% for the past two
decades. Non–small cell lung cancer (NSCLC) comprises approxi-
mately 80% of all lung cancers, and early-stage NSCLCs are poten-
tially curative by complete surgical resection. However, even with
surgical resection, the overall 5-year survival rate for these patients is
45% to 70%, with most deaths being due to metastatic recurrence.
The factors that are responsible for early metastasis in NSCLC remain
unknown. Deregulated overexpression of receptor tyrosine kinases has
been reported to promote tumor cell motility and invasion and has
been associated with poor prognosis.
The hepatocyte growth factor (HGF) receptor Met is a receptor ty-
rosine kinase that plays an important role in regulating cellular prolif-
eration, motility, morphogenesis, and apoptosis [1]. The c-met gene was
originally identified as a cellular counterpart of the chemically induced
oncogene tpr-met isolated from a human osteosarcoma cell line [4]. The
c-met gene encodes a high-affinity receptor for HGF [5]. HGF binding
activates the tyrosine kinase of Met receptor resulting in auto-
phosphorylation of several tyrosine residues in its cytoplasmic domain
[6,7]. The phosphorylation of each tyrosine residue initiates distinct
signal transduction cascades involving Erk, Akt, and Stat3 [6,7]. The
c-Met gene amplification and/or overexpression have been reported in
a wide variety of cancer types including lung, stomach, liver, prostate,
ovary, colon, and pancreatic cancers [8–13]. In lung adenocarcinoma,
Met protein expression assessed by immunohistochemistry has been
reported as an independent poor prognostic marker [14]. High serum
and tumor tissue levels of HGF have also been reported to predict poor
outcome in resected lung cancer patients [15,16]. The abrogation of
Met signaling by ribozymes, small interfering RNA, and chemical in-
hibitors has been reported to suppress the invasion and metastasis of
tumor cells [6,7]. Data suggest that the HGF-Met loop is one of the
factors that may promote metastasis in early-stage lung cancer [6,7].
However, direct experimental data to support this have not been forth-
coming. In this study, we evaluated the in vitro and in vivo effects of
forced co-overexpression of Met and HGF in the NCI-H460 human
large cell carcinoma cell line. Our results provide strong evidence that
ligand-dependent constitutive activation of Met in lung cancer cells
may promote systemic metastasis.
Materials and Methods
Animals and Cell Lines
Male nude (CR:NIH-RNU) rats (Charles River, Inc, Frederick
Cancer Research Facility, Frederick, MD) were received at 4 weeks of
age and acclimatized for 1 to 2 weeks before entering study protocols.
Rats were housed in sterilized cages and fed autoclaved food and water
ad libitum. Severe combine immunodeficient (SCID) mice were bred
on site and obtained from the Ontario Cancer Institute (OCI; Toronto,
Ontario, Canada) animal facility. All manipulations were done under
sterile conditions in a laminar flow hood, in accordance with procedures
approved by the Institutional Animal Care Committee at the OCI. The
general health of the animals was assessed daily.
NCI-H460 and Phoenix 293TAmpho cell lines were obtained from
the American Type Culture Collection (Rockville, MD). NCI-H460
cells were routinely cultured at 37°C inRPMI 1640medium containing
5% fetal bovine serum (FBS). Phoenix 293T Ampho were routinely
cultured in Dulbecco’s modified Eagle medium supplemented with
10% FBS. Retropack PT67 cell line was obtained from Clontech
(Mountain View, CA) and was routinely cultured in Dulbecco’s modi-
fied Eagle medium supplemented with 10% FBS.
Phospho-Met (Tyr1234/1235, catalog no. 3126 and 3077) anti-
bodies were purchased from Cell Signaling (Beverly, MA). Antibodies
against human Met (C28), murine Met (B3), and HGF were obtained
from Santa Cruz Biotech (Santa Cruz, CA). Human recombinant HGF
and anti-hHGF were purchased from R&D Systems (Minneapolis,
MN); human cytokeratin antibody, Cam 5.2 was from BD Company
(Mississauga, Ontario, Canada), CONFIRM c-Met (SP44) rabbit
monoclonal primary antibodywas obtained fromVentana (Tucson, AZ).
c-Met Expression Constructs
The pBMN-Met andHGF construct was created by cloning the full-
length human c-Met or hgf complementary DNA (cDNA) into the
pBMN-IRES-GFP retroviral vector. The pBMN-IRES-GFP plasmid
is part of the Phoenix Retroviral Packaging System (http://www.stan-
ford.edu/group/nolan/plasmid_maps/pmaps.html). The dominant-
negative met (dnMet) cDNA had three mutations (K1110A, Y1349F,
and Y1356F) that eliminated phosphorylation at the kinase domain
and the multifunctional docking site of the receptor. In addition, the
21–amino acid C-terminus of the humanmet cDNA has been replaced
by 12 amino acids of murinemet cDNA, allowing detection of this con-
struct in human cells by immunoblot analysis for murineMet [17]. This
dnMet cDNAwas directionally cloned into the EcoRI andNot1 sites of
pBMN-IRES-GFP. The EcoRI site was filled and destroyed during clon-
ing. An additional HGF construct (pLXSN-HGF) was generously pro-
vided by Dr. Morag Park (McGill University).
Stable Met- and HGF-Overexpressing Cell Lines
To generate retrovirus, either the Phoenix 293TAmphotropic retro-
viral, or the Retropack PT67, packaging line was transfected with
pBMN, pBMN-Met, pBMN-dnMet, pBMN-HGF or pLXSN-HGF
constructs using Lipofectamine PLUS transfection reagent (Invitrogen,
Burlington, Ontario, Canada). At 48 and 72 hours after transfection,
retrovirus-containing medium was harvested, and cell debris was re-
moved by centrifugation at 1500 rpm for 15 minutes. The H460 cells
were transduced with viral supernatants in the presence of 8 μg/ml
polybrene (Sigma Chemical, St Louis, MO) overnight. At 72 hours
after transduction, the cells were trypsinized into single-cell suspension
and sorted for high green fluorescent protein (GFP) expression by
fluorescence-activated cell sorting. Sorting attained a 90% to 95% pure
population of GFP expressing cells. Cell lines were monitored by flow
cytometry for GFP expression for 10 passages. If any loss of GFP oc-
curred, cells were resorted until the population stabilized (two sorts to-
tal). Stability of the line was monitored, and no loss of GFP expression
occurred in 10 passages. For pLXSN-HGF transductants, cells were
passaged 48 hours after transduction, and clones were selected with
0.8 mg/ml neomycin. The H460-HGF/Met cell line was generated
by viral transduction of pLXSN-HGF to the H460-Met cells and se-
lected by exposure to 0.8 mg/ml neomycin.
Messenger RNA Expression Assay
Total RNA (4 μg) was reverse-transcribed using Superscript II
reverse transcriptase (Invitrogen). A 10-ng equivalent of complemen-
tary DNA was used for each quantitative polymerase chain reaction
assay performed with the Stratagene Mx3000p Sequence Detection
System using SYBR green 2× master mix (Stratagene, La Jolla, CA).
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Intron-spanning primers for HGF and Met PCR amplification were
designed using the Primer Express software (Perkin-Elmer Applied
Biosystems, Foster City, CA). Primer sequences for human HGF
quantification were (forward) 5′-CCGAGGCCATGGTGCTATAC-3′
and (reverse) 5′-TCCTTGACCTTGGATGCATTC-3′. For human
c-Met, the primer sequences were (forward) 5′-ACCTTTGATATA-
ACTGTTTACTTGTTGCA-3′ and (reverse) 5′-GCTTTAGGG-
TGCCAGCATTTT-3′.
Western Blot Analysis
To extract total protein, cells and tumor tissues were homogenized in
lysis buffer (1%Triton X-100, 10% glycerol, 50mMHEPES, 150mM
NaCl, 1.5 mMMgCl2, 10 mM sodium pyrophosphate, 100 mMNaF,
10 mM Na4P2O4, 1 mM EDTA, 10 mg/ml aprotinin, 10 mg/ml leu-
peptin, 100 mg/ml phenylmethylsulfonyl fluoride, and 1 mM sodium
orthovanadate), and the lysates were cleared by centrifugation. Protein
samples were fractionated on SDS–polyacrylamide gel and transferred
to polyvinyliden fluoride membranes. The membranes were blocked
with Roche blocking reagent (Roche Diagnostics, Laval, Quebec,
Canada). Primary antibodies were used in the following concentra-
tions: hMet (100 ng/ml), mMet (200 ng/ml), pMet (Tyr1234/1235,
catalog no.3126; 200 ng/ml), and HGF (200 ng/ml). After incubations
with the appropriate secondary antibodies, immunoreactive protein
bands were detected by enhanced chemiluminescence (Roche Diag-
nostics Canada). Equal protein loading was confirmed by reprobing
the blot with antibody against reduced guanosine adenine dinucleo-
tide phosphate.
Subcutaneous Tumorigenicity Assay
Animal studies followed protocols that have been approved by the
institutional animal care committee. Two million cells were injected
subcutaneously in the left shoulder region of 5-week-old male SCID
mice (n = 8/cell line). Mice were examined every 2 days, and tumor
length and width were measured using calipers. Tumor volume was cal-
culated using the following formula (length × width2)π / 6. At 17 days,
mice were killed by CO2 asphyxiation, and tumors were excised. Por-
tions of tumors were snap-frozen and stored in liquid nitrogen or were
fixed in 10% buffered formalin for routine histopathologic processing.
Orthotopic Model to Evaluate Metastatic Potential
Six groups of rats (n = 8/group) were randomly assigned for ortho-
topic implantation of various engineered H460 lines. The cell lines
included H460-pBMN, H460-Met, H460-HGF, H460-dnMet,
H460-HGF/Met clone 4-8, and H460-HGF/Met clone 4-9. When
any animal from any group succumbed to the disease or demonstrated
terminal sign and symptoms, a single animal from each of the other
groups was killed. This allows a direct comparison of all groups at the
same time point for tumor-associated end points, including primary tu-
mor weight, mediastinal lymph node weight, and metastases. Survival
was not an end point of the study. Animals that died less than 21 days
after implantation were considered as postanesthetic or surgical-related
complications and were excluded from the final comparative analysis.
The procedure for endobronchial tumor cell implantation in nude
rats was previously reported in detail [18,19]. Before tumor implan-
tation, animals received 5-Gy whole-body γ-radiation using the Gam-
ma Cell 40 Exactor (Nordion International Inc, Ottawa, Ontario,
Canada; 500 rad of whole-body γ radiation from a 127Cs source
and at 120 rad/min). Cultured tumor cells were harvested by trypsi-
nization and adjusted to a final concentration of 1.5 × 106 cells/70 μl.
Rats were anesthetized by intramuscular injection of ketamine/
xylazine (110 and 12 mg/kg; CDMV, Inc, Guelph, Ontario, Canada)
and endobronchially implanted with 1.5 × 106 cells using a 20-gauge,
1.88-inch-long Teflon catheter. The catheter was passed into the distal
bronchus of right caudal lobe through a small tracheotomy incision. The
cell suspension was injected. After withdrawal of the catheter, the trache-
otomy was repaired with a 6-0 Proline suture (Ethicon, Inc, Sommer-
ville, NJ), and the incision was closed with sterile wound clips. The rats
were returned to their cages on sterile rolled drapes to maintain their
semiupright position.
Assessment of Metastatic Potential
Animals were killed when they succumbed to the disease or death
was pending because of tumor progression. Metastatic occurrences
were assessed macroscopically and microscopically. Any visible tumor
deposit other than the primary tumor was considered as metastasis.
The internal organs including lung, kidney, brain, chest wall, and bone
as well as mediastinal lymph nodes were removed from the killed ani-
mals. The specimens were weighed, fixed in 10% buffered formalin,
serially sectioned, and processed for histologic examination. Portions
of primary tumors were also harvested for snap freezing and storage
in liquid nitrogen.
The primary tumor and lymphnodeweights, which reflect the tumor
burden, were recorded. All tissues were serially sectioned and stained
with hematoxylin and eosin for microscopic examination. Any macro-
scopic or microscopic tumor deposit discovered, other than the primary
tumor, was considered a metastasis. Organs or tissues were counted as
either positive or negative for metastasis. No assessment of number or
extent of metastasis was made.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues were cut at 4-μm thickness
and dried in 60°C oven overnight. Sections were dewaxed in xylene and
rehydrated through graded alcohol to water. Endogenous peroxidase
was blocked in 3% hydrogen peroxide. Heat-induced epitope retrieval
was carried out in 10 mM citrate buffer, pH 6.0 in a Milestone T/T
Mega microwave oven. After blocking for endogenous biotin with
Vector’s biotin blocking kit, sections were incubated in primary anti-
body (h-Met [SP44; Ventana, Tucson, AZ]; HGF [AF-294-NA,
1:300 dilution; R&D Systems]; phospho-Met [Tyr1234/1235, catalog
no. 3077, 1:150 dilution; Cell Signaling]; mouse CD31 [sc-1506,
1:1000; Santa Cruz]) at room temperature in a moist chamber. After
washing in PBS, slides were incubated in biotin-conjugated anti-goat
IgG (HGF; Vector Laboratories, Burlingame, CA) or anti-rabbit IgG
(h-Met and pMet) followed by streptavidin-HRP (IDLabs Inc, London,
Canada) for 30 minutes each. Immunoreactivities were revealed by
incubating in NovaRed substrate (Vector Laboratories) for 5 minutes.
Slides were counterstained in Mayer’s hematoxylin and mounted
with Permount. Immunostaining for h-Met was performed using the
Ventana’s BenchMark XT System.
Assessment of Tumor Vascularity
Murine CD31 immunoperoxidase–stained sections were used to
highlight the blood vessels. Blood vessels were counted based on a pre-
viously describedmethod [20]. Any highlighted single endothelial cell or
cell clusters were separately counted from the adjacent vessels. Vascular
hot spots were selected on low magnification (100×), and the CD31-
positive vessels/cells were counted in five fields (20× objective) at a mag-
nification of ×200.
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ELISA Assay for HGF and Vascular Endothelial Growth
Factor Protein Levels
Using a DuoSet ELISA development system for human HGF and
vascular endothelial growth factor (VEGF; R&D Systems). Ninety-
six–well microplates (Nunc, Rochester, NY) were coated with 100 μl
per well of mouse antihuman HGF and/or VEGF diluted in PBS over-
night at 4°C. After blocking with 1% bovine serum albumin in PBS for
1 hour, plates were washed with PBS + 0.05% Tween 20 then 100 μl of
tumor lysates or standards in PBS + 1% bovine serum albumin were
added, and the plates were incubated for 2 hours at room temperature.
After washing, biotinylated goat antihuman HGF and/or VEGF detec-
tion antibody was added for 2 hours at room temperature. After several
washing steps, 100 μl of streptavidin-HRP was added to each well, and
the plates were incubated for 20 minutes at room temperature. After
washing, bound HGF and/or VEGF were revealed by reading absor-
bance at 450 nm. The assay was generally performed in duplicate.
Statistics
Two-way analysis of variance test was used to compare primary tumor
weight and lymph node weight. Difference in tumor growth rates of
xenografts was tested by using mixed-effects model estimation [21].
χ 2 and Fisher’s exact test were used to compare the incidence of metas-
tasis between each cell lines. Tests that produced P ≤ .05 were considered
Figure 1. Establishment of stable HGF/Met expressing H460 cell
lines. (A) The messenger RNA (mRNA) expression of human hgf
and c-met inHGF-,Met-, andMet/HGF–overexpressingH460 cell lines
were evaluated using RT-qPCR (data were expressed as relative level
of mRNA expression compared with pBMN control). (B and C) Met
and HGF H460 cell lines with or without HGF stimulation (20 ng/ml)
were analyzed by Western blot for the activated receptor using
phospho-Met–specific antibody (pMet—top panel) and the total
Met receptor levels using human Met antibody (hMet—bottom
panel). (C) dnMet-H460 cell line was used as a negative control. The
accuracy of dnMet-H460 cell line was measured using antibody
specific formouse c-Met. No phosphorylation of c-Metwas observed
in dnMet-H460 cell line both in the absence and in the presence
of HGF.
Figure 2. HGF/Met–overexpressing H460 tumor growth rate
in vivo. (A and B) Experiment conducted in duplicate, and data
are represented as mean ± SEM (n= 8). (C) Primary tumor weight.
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to be significant. For the rest of other experiments, Mann-Whitney test
was used.
Results
Establishment of H460 Met– and HGF-Overexpressing
Cell Lines
Stable integration and expression of human Met receptor and HGF
(hHGF) in H460 cells was monitored for more than 10 passages and
confirmed by quantitative reverse transcription–PCR (RT-qPCR; Fig-
ure 1A) and Western blot analysis (Figure 1B). Expression of c-met
but not hgf cDNA resulted in the HGF-independent constitutive
activation of the receptor, as detected by Western blot with the anti-
body specific to phosphorylated Y1234,1235Met (catalog no. 3126; Fig-
ure 1, B and C ). Clones that overexpressed both Met and HGF
(H460-HGF/Met 4-8 and 4-9) showed increased levels of phospho-
Met compared with the H460-Met cell line (Figure 1B). Overexpres-
sion of HGF or HGF/Met did not alter the morphology of the cells
(Figure W1), and they remained epithelial in appearances (Figures W2
and W3). HGF-overexpressingH460 cells showed compensatory down-
regulation of Met protein level (Figure 1, B and C). The dnMet-H460
cell line suppressed the phosphorylation of the Met receptor even in
the presence of the HGF ligand (Figure 1C ).
Effect of Met and/or HGF Overexpression on Tumorigenicity
of H460 Cells
When implanted subcutaneously in SCID mice, the H460-HGF
and H460-Met cells showed growth rates similar to the H460-pBMN
control cells (Figure 2A). In contrast, the H460-HGF/Met 4-8 and 4-9
clones showed increased growth rate compared with the H460-pBMN
control cells (Figure 2B). The H460-HGF/Met 4-8 cells demonstrated
increased growth rate (P = .0034) and tumor weight (P = .0203; Fig-
ure 2C ). The expression of c-met and hgf in H460-tumor lines was
verified by RT-qPCR (Figure 3, A and B). The increased constitutive
activation of Met in tumors was also confirmed in H460-Met and both
clones ofH460-HGF/Met byWestern blot analysis (Figure 3,C andD)
and immunohistochemistry (Figure 4A) using phosphorylated Met
specific antibody (Tyr1234/1235, catalog no. 3077). As a control, we
showed that the dnMet-H460 tumor cells had markedly reduced Met
Figure 3. Expression of c-Met and hHGF in H460 tumors. (A and B) mRNA expression of human hgf and c-metwas verified using RT-qPCR.
(C) HGF and Met overexpression was detected in H460 tumors using Western blot for hHGF and c-Met and the activated Met receptor.
H460-dnMet was used as a negative control. (D) Histogram shows the ratio between the two bands (phosphoprotein and total protein)
relative to pBMN control. The intensity of the bands was measured using the microcomputer imaging device (MCID) program.
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receptor phosphorylation when compared with the Met-H460 tumor
cells (Figure 3C and Figure W4).
HGF Enhances Angiogenesis in HGF/Met–Overexpressing Cells
Tumor angiogenesis was assessed by both qualitative method and
intratumoral microvessel density assessment using staining with
antimouse antibody to endothelial marker CD31 (mCD31). H460-
HGF/Met 4-8 and 4-9 tumors showed higher intratumoral microvessel
density than the control H460-pBMN (P = .008), H460-HGF, and
H460-Met tumors (Figure 4B). Quantitative measurement of human
HGF by ELISA showed the highest HGF content in H460-HGF,
H460-HGF/Met 4-8, and 4-9 tumors compared with control H460-
pBMN and H460-Met tumors (P = .0002; Figure 4C). In contrast, the
VEGF contents of H460-HGF/Met tumors were lower than tumors
formed by the other cell lines (Figure 4D), indicating that the increased
vascularity in the former was most likely due to the overexpression of
both Met and HGF.
HGF/Met Co-overexpression Enhanced Metastatic Potential
of H460 Cells
Orthotopic implantation of lung cancer cells has been reported to
mimic more the behavior of human lung cancer than the subcutaneous
model [22]. Similar to the parental H460 line, H460-pBMN devel-
oped regional metastasis to mediastinal lymph nodes but very limited
systemic metastases (1/7) to distant organs (Table 1). No significant
differences were noted in the weight of the primary tumors formed
by all cell lines. Both H460-Met and H460-HGF cells showed in-
creased metastases to the bone, kidneys, and left lung but not to the
brain and gum. Metastases to both the bone and kidneys appeared
increased further in H460-HGF/Met cells (Table 1). Only the HGF/
Figure 4. Constitutive activation of Met and HGF induced angiogenesis in HGF/Met–overexpressing H460 xenograft tumors. (A) Immuno-
histochemistry of xenografts formed by H460 cell lines without (pBMN) or with HGF and/or Met overexpression. (B) Number of mCD31-
positive blood vessels in five fields of most vascular areas at 200×magnification. (C and D) Concentration of HGF and VEGF, respectively, in
protein extracts of xenograft tumors by ELISA. Magnifications: ×100 for HGF; ×200 for h-Met and pMet. Asterisks (*) indicate statistical
significance between groups.
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Met 4-9 cells that have the highest levels of Met and HGF coexpression
showed increased metastases to the brain and gum. Overall, only the
H460-HGF/Met clones produced statistically significant systemic
metastases (7/8 and 8/8, respectively) in the experimental animals when
compared with the H460-pBMN cells (P < .05; Table 1).
Using the HGF and Met antibody, tumors formed by the H460-
HGF/Met 4-9 cells showed increased Met and HGF expression in
both the primary and metastatic organ (lymph node) compared with
pBMN control cells (Figure 5).
Discussion
We have demonstrated that overexpression of Met receptor with or
without HGF co-overexpression in the H460 lung cancer cell line
resulted in ligand-independent, constitutive activation of the receptor.
In contrast, HGF overexpression alone did not. Whereas overexpres-
sion of either Met or HGF individually increased modestly the systemic
metastasis of H460 cells, especially to bone and/or kidney, the co-
overexpression of both the ligand and receptor further enhanced the
metastatic potential of these cells. These results provide direct evidence
that autocrine overactivation of the HGF-Met loop may promote sys-
temic metastasis in NSCLC.
There is evidence that HGF and/or Met overexpression is associated
with poor survival in NSCLC patients [11,14,23]. The coexpression
of both HGF and Met has been detected in 50% to 52% of lung
primary adenocarcinomas [13,14]. The HGF-Met system is currently
thought to function mainly in a paracrine manner [24–26], with the
tumor cells expressing the receptor and the ligand originating from
the stromal fibroblasts. However, we have previously shown that
HGF is expressed in primary NSCLC and by normal bronchial epithe-
lial cells and many NSCLC cell lines that also demonstrated constitu-
tive Met receptor autophosphorylation [27]. Autocrine HGF-Met
signaling plays significant roles in the scattering activity, growth, and
differentiation of human lung adenocarcinoma cells [28,29]. Autocrine
Table 1. Effect of HGF/Met Expression on Metastases.
Cell Line T wt (g), mean ± SD LN wt (g), mean ± SD Regional Mets
No. Animals
Systemic Mets No. Animals
LN L. lung Bone Kidney Brain Gum Systemic mets Total No. animals
pBMN 4.6 ± 1.7 0.21 ± 0.21 7 2 0 1 1 0 1 7
HGF 4.1 ± 2.4 0.19 ± 0.27 8 7 4 2 1 1 4 8
Met 4.7 ± 3.1 0.36 ± 0.36 8 7 2 3 1 2 5 9
HGF/Met 4-8 4.4 ± 3.8 0.29 ± 0.22 8 7 4 6 1 2 7* 8
HGF/Met 4-9 4.9 ± 2.6 0.49 ± 0.47 7 7 6 7 4 4 8* 8
L. lung indicates left lung; LN, lymph node; mets, metastasis; T, primary tumor; wt, weight.
Incidence of systemic metastasis in orthotopic model using nude rat. The metastatic potential of lung cancer cell lines is demonstrated by their endobronchially orthotopic implantation of 1.5 × 106 cells/
70 μl in the right caudal lobe. Animals were killed when they succumbed to the disease or death was pending owing to tumor progression. Metastatic occurrences were assessed macroscopically and
microscopically. Any visible tumor deposit other than the primary tumor was considered as metastasis. Primary tumor weight and the weight of the mediastinal lymph node were measured to evaluate
tumor burden.
*The H460-HGF/Met clones produced statistically significant systemic metastases (7/8 and 8/8, respectively) in the experimental animals when compared with the H460-pBMN cells (P < .05).
Figure 5.Metastatic potential of H460 cells implanted orthotopically is dependent on both HGF andMet expression. Immunohistochemistry
evaluation of HGF andMet in lymph nodes of representative tissues fromHGF/Met overexpressing H460 cell line clone 4-9 and control H460
cell line harboring empty vector (H460-pBMN).
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Met-HGF expression has also been shown to be able to mediate tumor-
igenicity and metastasis in NIH 3T3 cells [30,31]. However, before the
current study, it was unknown whether autocrine HGF-Met signaling
was important in lung cancer metastasis.
Our laboratory has previously reported that the orthotopic implan-
tation of H460 human lung carcinoma cell line could metastasize spon-
taneously to systemic organs [12,19], thus more accurately mimicking
the progression of human lung cancer. The model involves two stages.
First, the orthotopic implantation of H460 cells resulted in only medi-
astinal lymph node metastasis. Second, when the primary tumor was
harvested and reimplanted into new hosts, systemic metastases to the
bone, kidney, brain, and soft tissue such as gum were observed. Using
this orthotopic model, the H460 overexpressing both Met and HGF
resulted in spontaneous systemic metastasis without the two-stage
process required for the parental H460 cells alone. However, only
the H460-HGF/Met 4-9 cells demonstrated the highest spontaneous
metastases to bone, kidney, brain, and gum. In contrast, the H460-
HGFor -Met alone showed lessmetastases to all these sites. Interestingly,
the H460-HGF/Met 4-8 cells also showed high metastatic rate to bone
and kidney comparable to the 4-9 clone but demonstrated reduced
metastases to brain and gum. Compared with the 4-9 clone, the
H460-HGF/Met 4-8 cells showed a low level of Met autophosphoryla-
tion. This effect may arise from clonal variation leading to a reduced
autocrine activity. This suggests that the HGF-Met autocrine loop plays
a greater role in brain and gum metastases in this model. We have
reported previously that an H460SM cell line selected for their spon-
taneous systemic metastasis ability similar to the H460-HGF/Met
cells also showed increased expression of Met compared with the pa-
rental H460 cells, further supporting the importance of the HGF-
Met loop in inducing systemic metastasis [32]. In this regard, we cannot
rule out that Met overexpression alone may be sufficient to promote
metastasis because mouse HGF does not react and activate human
Met receptor [33].
We have also shown that the HGF/Met co-overexpressing cells
form tumors with both increased vascularity and higher HGF tumor
content. However, the H460 cells that overexpress HGF alone also
highly express the VEGF yet did not show comparable metastatic
potential. The finding indicates that increased vascularity and high
HGF expression are not the only mechanism to increase metastasis.
We previously reported that, in the NCI-H358 lung adenocarcinoma
cells that have functionally active cell surface Met receptor, overexpres-
sion of HGF enhanced the cells’ capacity to colonize soft agar and
form subcutaneous xenograft tumors in SCID mice, without affecting
the expression of VEGF [28]. Therefore, we postulate that the autocrine
overactivation of the HGF-Met loop in NSCLC cells induces the ex-
pression of factors that further enhance angiogenesis, in addition to
HGF and/or VEGF. Using gelatin zymography, we observed higher
levels of both proactive and active forms (72 and 68 kDa, respectively)
of MMP-2 and of MMP-9 (92 and 82 kDa, respectively) in the
H460-HGF/Met tumors compared with control H460-pBMN
(Figure W5). In this regard, we believe that the activity of MMP-2
and MMP-9 may also contribute to the enhanced angiogenesis and
metastatic potential.
The necessity for coordinated activation of HGF and Met suggests
that the tumor cells need to have co-overexpression of HGF and Met
for theirmaximum effect on the promotion ofmetastasis. To our knowl-
edge, there is no direct evidence stating that autocrine mechanism of
HGF-Met signaling potentiates the metastasis of NSCLC cells. We
believe that the orthotopic H460-HGF/Met models are good models
to test Met or HGF inhibitors for their potential use in adjuvant therapy
for lung cancer.
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Supplemental Materials and Methods
Gelatin Zymography
Xenograft tumors from inoculating H460 cell line together with
H460-pBMN vector control and H460-pBMN harboring Met,
HGF, and HGF/Met co-overexpressing cell lines (clones 4-8 and 4-9)
were homogenized in lysis buffer (1% Triton X-100, 10% glycerol,
50 mMHEPES, 150 mMNaCl, 1.5 mMMgCl2, 10 mM sodium py-
rophosphate, 100 mM NaF, 10 mM Na4P2O4, 1 mM EDTA, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 100 mg/ml phenylmethylsulfonyl
fluoride, and 1 mM sodium orthovanadate), and the lysates were
cleared by centrifugation. The conditioned media from cell lines were
collected after 48 hours of serum starvation of the cells. Proteins (30 μg
per sample) were diluted in nonreduced SDS sample buffer and sepa-
rated by electrophoresis in 10% SDS–polyacrylamide gels copolymer-
ized with 1 mg/ml gelatin (for MMP-2 and MMP-9 activity
detection). Gels were washed with 2.5% Triton X-100 for 1 hour and
then twice in Tris-HCl (pH 8.0) for 15 minutes at room temperature.
The gels were incubated with substrate buffer (50 mM Tris-HCl
[pH 8.0] and 10 mM CaCl2) for 18 hours at 37°C. The gels were then
stained withCoomassie brilliant blue and destained until the clear bands
of lysis appeared. To confirm the lytic bands, gels were treated with
20 mM EDTA (a metalloproteinase inhibitor) in the substrate buffer
for 18 hours at 37°C.
Figure W1. Overexpression of HGF in H460 cell lines had no effect on cell morphology. The morphology of HGF-, Met-, and HGF/Met–
overexpressing H460 cell lines were visualized after staining them with crystal violet (0.2%).
Figure W2. Expression of E-cadherin in high hHGF/Met–expressing
cells. ThemRNAexpressions of hHGF, c-Met, andE-cadherin inHGF/
Met 4-9 H460 cell lines with a high expression level of c-Met were
evaluated using RT-qPCR and compared with the expression level
of the same genes in HGF/Met 4-9 H460 cell lines with a low expres-
sion level of c-Met.
Figure W3. HGF and cytokeratin expression in xenograft tumors appeared to be homogenous, and cells are considered to be epithelial.
Xenograft tumors from inoculation of stable HGF- and HGF/Met 4-9–overexpressing H460 cell lines were analyzed by immunohisto-
chemistry for the hHGF (R&D Systems), and human cytokeratin Cam 5.2 (BD Company) specific antibodies at a magnification of ×400.
Figure W4. Xenograft tumors from inoculation of stable dnMet and co-overexpressing HGF/Met-H460 (clone 4-9) cell lines were analyzed
by immunohistochemistry for the activated receptor using phospho-Met–specific antibody (pMet) at a magnification of ×400.
Figure W5. Enhanced activity of MMP-9 and MMP-2 in HGF/Met–overexpressing H460 cell lines. (A and B) Using gelatin zymography in
both in vitro (A) and in vivo (B), we demonstrated higher levels of both proactive and active form of MMP-9 (92 and 82 kDa, respectively)
and MMP-2 (72 and 68 kDa, respectively) when both HGF and c-Met were overexpressed compared with pBMN control and parent H460.
The bands show the lytic zones.
